obsolete recurrent cancer of Liver

Recurrent Liver Cancer: Signs and Symptoms

Liver cancer recurrence can be challenging to detect, but there are some common signs and symptoms that may indicate its presence. While these symptoms can also be associated with other conditions, it's essential to be aware of them, especially if you have a history of liver cancer.

• Abdominal pain: Pain in the right upper abdomen or shoulder blade is a common symptom of liver cancer recurrence (see [6] and [9]). This pain can range from mild to severe and may worsen over time.
• Weight loss: Unintended weight loss, often accompanied by loss of appetite, is another sign of liver cancer recurrence (see [5] and [8]).
• Jaundice: A yellowish discoloration of the skin and eyes, known as jaundice, can be a symptom of liver cancer recurrence (see [6]).
• Loss of appetite: Decreased appetite is a common symptom of liver cancer recurrence (see [5], [8], and [9]).
• Bloating and abdominal distension: Fluid accumulation in the abdomen, also known as ascites, can cause bloating and discomfort (see [9]).

It's essential to note that these symptoms can be vague and may not necessarily indicate liver cancer recurrence. If you experience any of these symptoms, it's crucial to consult with your healthcare provider for a proper evaluation and diagnosis.

Monitoring and Follow-up

If you have a history of liver cancer, regular check-ups with your doctor are vital to monitor for signs of recurrence (see [7]). Your healthcare provider may recommend imaging tests, such as CT or MRI scans, to detect any potential recurrences.

Citations: [5] - Context result 5 [6] - Context result 6 [7] - Context result 7 [8] - Context result 8 [9] - Context result 9

Based on the provided context, it appears that there are various diagnostic tests used to detect and monitor liver cancer recurrence. Here are some of the relevant tests mentioned:

• Imaging tests: These include CAT (computed axial tomography) scans, MRI (magnetic resonance imaging), and others, which can help identify suspicious areas in the liver and determine the extent of cancer spread [1][6].
• Blood Tests: This includes a test that looks for elevated levels of alfa-fetoprotein (AFP), which may be a sign of hepatocellular carcinoma [8].
• Liver function tests (LFTs): These tests can help assess liver damage and function, which is essential in monitoring liver cancer recurrence [4].
• Coagulation studies: Tests such as the international normalized ratio (INR) can help evaluate blood clotting and bleeding risks associated with liver cancer [4].

Additionally, some studies have explored the use of tumor markers, such as AFP and PIVKA-II, to predict liver cancer recurrence [9]. However, more research is needed to confirm their effectiveness.

It's worth noting that the diagnosis of liver cancer recurrence often involves a combination of these tests, along with clinical evaluation and patient history. A healthcare provider will typically use a multi-disciplinary approach to determine the best course of action for each individual case.

References:

[1] Context result 3 [4] Context result 4 [6] Context result 6 [8] Context result 8 [9] Context result 9

Treatment Options for Recurrent Liver Cancer

Recurrent liver cancer, also known as hepatocellular carcinoma (HCC), can be challenging to treat. While there are no guarantees of success, various treatment options are available to manage the disease and improve quality of life.

• Targeted Therapy: This is the standard treatment for recurrent liver cancer. Targeted therapy uses drugs to target specific molecules on cancer cells or inside them, stopping their growth and spread while minimizing harm to normal cells.
  • The targeted therapy drugs used for recurrent liver cancer are:
    1. Atezolizumab (Tecentriq) plus bevacizumab (Avastin)
    2. Cabozantinib
    3. Nivolumab
• Immunotherapy: Immunotherapy is a type of treatment that uses the body's immune system to fight cancer. In the case of recurrent liver cancer, immunotherapy can be used in combination with other treatments.
  • Atezolizumab (Tecentriq) plus bevacizumab (Avastin) has been approved by the FDA as an initial treatment for some people with advanced liver cancer.
• Chemotherapy: Chemotherapy is a type of treatment that uses drugs to kill cancer cells. While chemotherapy can be effective in treating recurrent liver cancer, it may not be suitable for everyone.
  • Following surgery to remove liver metastases, chemotherapy is often used to decrease the chance of tumor recurrence.
• Ablation Therapy: Ablation therapy removes or destroys tissue. Different types of ablation therapy are used for liver cancer, including radiofrequency ablation (RFA) and microwave ablation (MWA).
  • RFA can be used to treat small tumors in the liver.

Newer Treatment Options

Recent studies have explored new treatment options for recurrent liver cancer, including:

• Stereotactic Body Radiation Therapy (SBRT): SBRT is a type of radiation therapy that delivers high doses of radiation to specific areas of the body. It can be used to treat small tumors in the liver.
  • A study published in 2022 found that SBRT was effective in treating small HCCs and improving overall survival.
• Adjuvant Immune Checkpoint Inhibitors (ICIs): ICIs are a type of immunotherapy that can be used to improve recurrence-free survival (RFS) in patients with HCC at high risk of recurrence.
  • A study published in 2022 found that adjuvant ICI treatment duration was associated with improved RFS and overall survival among patients with HCC.

Conclusion

While there is no cure for recurrent liver cancer, various treatment options are available to manage the disease and improve quality of life. Targeted therapy, immunotherapy, chemotherapy, ablation therapy, SBRT, and adjuvant ICIs are some of the treatment options that can be used to treat recurrent liver cancer. It's essential to discuss these options with a healthcare professional to determine the best course of treatment for individual patients.

Sources:

• A study published in 2022 found that targeted therapy was effective in treating small HCCs and improving overall survival.
• Atezolizumab (Tecentriq) plus bevacizumab (Avastin) has been approved by the FDA as an initial treatment for some people with advanced liver cancer.
• Following surgery to remove liver metastases, chemotherapy is often used to decrease the chance of tumor recurrence.

The differential diagnosis of recurrent liver cancer involves considering various conditions that may mimic or be confused with liver cancer recurrence. Based on the search results, here are some key points to consider:

• Other malignant tumors: The differential diagnosis between the recurrence of hepatocellular carcinoma (HCC) and other malignant tumors, such as intrahepatic cholangiocarcinoma (ICC), should be considered [4].
• Atypical hemangioma and ICC: Caution should be used in the interpretation of nodules that may resemble HCC, as they can also be atypical hemangiomas or ICC [7].
• Cirrhotic liver: The differential diagnosis from cirrhotic liver is an important consideration, and even needle biopsy may be necessary in some cases [12].
• Benign hepatocellular tumors: A biomarker panel in combination with other tissue-specific markers could represent a useful tool for diagnosis and differential diagnosis between benign and malignant hepatocellular tumors, HCC and ICC [13].

In addition to these points, it's also worth noting that the workup of HCC should include markers of stem cellness, such as CK-19, as tumors expressing these markers have increased chemoresistance, earlier recurrence [5]. Furthermore, after diagnosis of HCC recurrence, staging should begin with the search for evidence of extrahepatic disease [14].

Overall, a comprehensive differential diagnosis of recurrent liver cancer requires careful consideration of various conditions that may mimic or be confused with liver cancer recurrence.

References:

[4] Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: a systematic review. [7] Jiang Y, Jin L, Zhang T, et al. Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990-2017. [12] Tian HY, et al. Ultrasonography and enhanced computed tomography features of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a systematic review. [13] Mamone G. Biomarkers for liver cancer diagnosis and differential diagnosis between benign and malignant hepatocellular tumors. [14] Am J Med Sci, 354 (2017), pp. 262-267, 10.1016/j.amjms.2017.05.014.